辛伐他汀对慢性阻塞性肺病患者缓解期的影响研究

目的探讨辛伐他汀对慢性阻塞性肺病稳定期患者肺功能及炎症递质的影响。方法入选86例慢性阻塞性肺病患者,其分级处于Ⅰ~Ⅲ级的稳定型,进入研究前至少4周未使用抗生素或口服皮质类固醇激素,随机分为两组：治疗组（41例）口服辛伐他汀,每晚口服辛伐他汀20mg,连续12周,对照组（45例）口服安慰剂。比较用药前后TNF-α,CRP、FEV1、FEV1/FVC,胆固醇和低密度脂蛋白的变化情况。结果辛伐他汀组治疗前TNF-α为（28.34±6.13）pg/ml,治疗后为（20.30±6.28）pg/ml;C反应蛋白治疗前为（4.26±3.70）mg/L,治疗后为（2.64±1.80）mg/L;FEV1治疗前为（1.14±0.44）L,治疗后为（1.16±0.45）L;FEV1/FVC治疗前为（47.80±9.88）%,治疗后为（53.77±11.26）%。对照组TNF-α,FEV1,FEV1/FVC治疗前后无明显差异。结论辛伐他汀能减少COPD患者缓解期肿瘤坏死因子α及C反应蛋白分泌,但对FEV1及FEV1/FVC百分比无明显改善,这并不排除治疗时间偏短的影响因素,可适当延长观察时间重新评价。

The Influence Of Simvastatin with Stable COPD Patient

Objective Through taking in simvastatin in treating group is to investigate the influence of simvastatin on inflammatory factors and lung function in stable patients with COPD.Methods Eighty-six stable COPD patients who came from the clinical or in-hospital patients between 2007.10—2009.02 years in the forth people hospital.All recruited COPD patients were diagnosed according to the COPD diagnose-cure guide(2007 revised edition) on COPD criteria.They belong to Ⅰ-Ⅲ stable grades.Results After the treatment,the serum TNF-α counts28.34±6.13pg/ml pre-treatment vs 20.30±6.28 pg/ml post-treatmentand CRP(4.26±3.70)mg/L pre-treatment vs(2.64±1.80)mg/L post-treatment in the simvastatin group were Significant change while the other comfort group observation items and the FEV1 counts(1.14±0.44)L pre-treatment vs(1.16±0.45)L post-treatment;FEV1/FVC(47.80±9.88)% pre-treatment vs(53.77±11.26)% post-treatment changed not notably.Conclusion Simvastatin used in stable COPD patients can decrease TNF-αand CRP secreting,but it is no use to FEV1,FEV1/FVC.The result can not exclude the influence of short treatment term.Maybe the result can be made by prolonging the treatment time.